ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Rhea-AI Summary

ADC Therapeutics has announced the acceptance of pivotal Phase 2 trial results for camidanlumab tesirine (Cami) in relapsed or refractory Hodgkin lymphoma for an oral presentation at EHA2022 in Vienna, Austria, from June 9-12, 2022. The company expresses optimism regarding Cami’s efficacy and safety as a single-agent therapy, with potential for a Biologics License Application submission. Additionally, data related to ZYNLONTA in diffuse large B-cell lymphoma will be presented in various formats at the congress.

Positive

• Pivotal Phase 2 trial results for Cami accepted for oral presentation at EHA2022.
• Encouraging data showing Cami's efficacy and safety for Hodgkin lymphoma patients.
• Potential for BLA submission for Cami, indicating advancement toward regulatory approval.

Negative

• None.

Oral presentation of pivotal Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma

ZYNLONTA® diffuse large B-cell lymphoma data highlighted in several abstracts

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association 2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022.

“We continue to be encouraged by the data from our ongoing pivotal Phase 2 trial demonstrating the efficacy and safety of Cami as a single agent for patients with relapsed or refractory Hodgkin lymphoma,” said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. “As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.”

Details of ADC Therapeutics’ oral presentation are as follows:

Camidanlumab Tesirine: Updated Efficacy And Safety In An Open-Label, Multicenter, Phase 2 Study Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (R/R CHL)
Presentation Date and Time: Friday, June 10, 2022, 11:45 am – 12:00 pm CEST // 5:45 am – 6 am EDT
Session Title: Hodgkin lymphoma – Clinical
Session Room: Hall A8
Abstract Code: S201
Presenter: Carmelo Carlo-Stella, MD, Department of Biomedical Sciences, Humanitas University, and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy

Details of ADC Therapeutics’ poster presentations are as follows:

Health-Related Quality Of Life And Tolerability Of Loncastuximab Tesirine In High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated In A Phase 2 Clinical Trial (LOTIS 2)
Session Date and Time: Friday, June 10, 2022, 16:30 – 17:45 CEST // 10:30 am – 11:45 am EDT
Location: Hall D
Abstract Code: P1717

Real-World Characteristics And Clinical Outcomes In Relapse/Refractory Diffuse Large B-Cell Lymphoma Patients Who Received Car-T Therapy
Session Date and Time: Friday, June 10, 2022, 16:30 – 17:45 CEST // 10:30 am – 11:45 am EDT
Location: Hall D
Abstract Code: 1182

Real-World Characteristics And Clinical Outcomes In Relapse/Refractory Diffuse Large B-Cell Lymphoma Post Car-T Failure
Session Date and Time: Friday, June 10, 2022, 16:30 – 17:45 CEST // 10:30 am – 11:45 am EDT
Location: Hall D
Abstract Code: 1181

Titles of ADC Therapeutics’ abstracts accepted for publication only are as follows:

• A Phase 2, Open-Label Study Of Loncastuximab Tesirine In Combination With Rituximab (LONCA-R) In Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9) [Trials in progress]
• Long‐term survival projections of loncastuximab tesirine‐treated patients in relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL)
• Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca‐R) Versus Immunochemotherapy in Patients With R/R DLBCL (LOTIS‐5) [Trials in progress]

Please note: times and locations are tentative and subject to change.

About Camidanlumab Tesirine (Cami)

Camidanlumab tesirine (Cami) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload, killing the cell. This applies to CD25-expressing tumor cells and also to CD25-expressing Tregs. The intra-tumoral release of its PBD payload may also cause bystander killing of neighboring tumor cells, and PBDs have also been shown to induce immunogenic cell death. All of these properties of Cami may enhance immune-mediated anti-tumor activity.

Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.

About ZYNLONTA® (loncastuximab tesirine-lpyl)

ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.

The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005635/en/

Investors



Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205

Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

+1 917-288-7023

EU Media

Alexandre Müller

Dynamics Group

amu@dynamicsgroup.ch

+41 (0) 43 268 3231

USA Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics SA

FAQ

What are the results of the Phase 2 clinical trial for ADCT's Cami?

The pivotal Phase 2 trial results for camidanlumab tesirine (Cami) in relapsed or refractory Hodgkin lymphoma have shown encouraging efficacy and safety, with a presentation scheduled at EHA2022.

When is the EHA2022 presentation for Cami by ADC Therapeutics?

The oral presentation for Cami is scheduled for June 10, 2022, from 11:45 am to 12:00 pm CEST at the EHA2022 in Vienna.

What data will ADC Therapeutics present at EHA2022?

ADC Therapeutics will present data on camidanlumab tesirine (Cami) and ZYNLONTA, highlighting their efficacy and safety in treating various forms of lymphoma.

What is ZYNLONTA and its relevance to ADC Therapeutics?

ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody drug conjugate approved for treating relapsed or refractory large B-cell lymphoma, demonstrating ADC Therapeutics' advancements in cancer therapeutics.